Cervical cancer vaccine launch in few months, to be priced between ₹200-400: Adar Poonawalla

India's first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) vaccine for the prevention of cervical cancer will be launched in few months, SII's Adar Poonawalla said on 1 September.

He further added that the vaccine will be available to the people in an affordable price range of ₹200-400.

"The cervical cancer vaccine will be affordable and would be available in the range of ₹200-400. However, the final price is yet to be decided", he said.

Adar Poonawalla attended an event along with Union Minister of Science and Technology Jitendra Singh on Thursday to announce the scientific completion of the vaccine. 

Scientific completion implies that R&D activities pertaining to the vaccine are complete and now the next step of making them available to the public would take place.

Speaking at the event, Singh said Covid has raised awareness about preventive healthcare leading to the development of vaccines like the one against cervical cancer.

"The schemes like Ayushman Bharat have made us think about preventive healthcare and we can now afford it. The Department of Biotechnology has taken a lead in the matter and are in collaborative mode," he said.

"Scientific efforts at times do not get the scale of recognition they deserve. So this event is to celebrate that scientific completion," he said.

Poonawalla also said, “First the vaccine would be made available through the government channel and from next year onwards some private partners would be involved too.”

Poonawalla also said that a plan to make 200 million doses is in place and first the vaccine would be given in India and only after that it will be exported to other countries.

Rajesh Gokhale, Department of Biotechnology Secretary, said over 2000 volunteers participated across the country for this vaccine.

"Partnerships between private-public are becoming very important in such research, this co-creation is what is going to make all the difference in the world," he said.

Dr N Kalaiselvi, Director General, CSIR said this is the first stepping stone and research in the field and it will further continue.

"This government has taken the most amount of care to come up with this type of innovation, making us 'atmanirbhar'," she said.

According to the officials, the qHPV vaccine CERVAVAC has demonstrated robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups.

Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.

The Drugs Controller General of India (DCGI) had in July granted market authorisation to the SII to manufacture the vaccine against cervical cancer.

(With inputs from PTI)